2. Is Advanced Enzyme Technologies Ltd undervalued or overvalued?
The key valuation ratios of Advanced Enzyme Technologies Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
3. Is Advanced Enzyme Technologies Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Advanced Enzyme Technologies Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
10 Year X-Ray of Advanced Enzyme:
Analysis of Financial Track Record
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Advanced Enzyme Technologies Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
Value Creation Index Colour Code Guide
ⓘ
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
Mar'24
TTM
ROCE % ⓘ
13.8%
14.3%
18.1%
15.1%
14.9%
21.5%
24.2%
15.8%
14.8%
24.3%
-
Value Creation Index ⓘ
0.0
0.0
0.3
0.1
0.1
0.5
0.7
0.1
0.1
0.7
-
Growth Parameters ⓘ
Growth Parameters Colour Code Guide
ⓘ
Sales ⓘ
126
139
173
212
222
247
283
273
312
365
351
Sales YoY Gr.
-
10.5%
24.1%
22.8%
4.7%
11.4%
14.6%
-3.8%
14.2%
17.3%
-
Adj EPS ⓘ
1.9
2
3.1
3.2
3.2
5.2
6.3
4.8
5
10.8
9.2
YoY Gr.
-
5.9%
58.1%
1.9%
-0.9%
64.6%
21.7%
-24.2%
3.3%
118.4%
-
BVPS (₹) ⓘ
14.3
16
22.8
25.6
28.3
32.9
38.7
42.9
47
51.6
56.3
Adj Net Profit ⓘ
20.4
21.6
34.9
35.6
35.3
58.1
70.7
53.7
55.5
121
102
Cash Flow from Ops. ⓘ
33.5
22.3
21.1
22.6
35.4
46
84.2
37.1
50.3
55.8
-
Debt/CF from Ops. ⓘ
1.2
2.2
1.8
2
0.6
0.2
0
0
0
0
-
CAGR ⓘ
CAGR Colour Code Guide
ⓘ
9 Years
5 Years
3 Years
1 Years
Sales ⓘ
12.6%
10.5%
8.8%
17.3%
Adj EPS ⓘ
21.6%
27.9%
19.6%
118.4%
BVPSⓘ
15.3%
12.8%
10.1%
9.9%
Share Price
-
13.7%
2.3%
-22.2%
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide
ⓘ
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
Mar'24
TTM
Return on Equity % ⓘ
13.9
13.1
16.3
13.1
11.6
16.8
17.6
11.7
11
21.9
17
Op. Profit Mgn % ⓘ
28.1
26.8
28.4
23.3
23.9
31.5
35.7
26.7
24.4
28.8
20.1
Net Profit Mgn % ⓘ
16.2
15.5
20.2
16.8
15.9
23.5
25
19.7
17.8
33.1
29.1
Debt to Equity ⓘ
0.3
0.3
0.2
0.2
0.1
0
0
0
0
0
0
Working Cap Days ⓘ
236
224
199
205
234
223
203
230
220
194
136
Cash Conv. Cycle ⓘ
142
134
125
113
113
120
106
124
126
128
110
Recent Performance Summary
Return on Equity has increased versus last 3 years average to 17.00%
Net Profit is growing at healthy rate in last 3 years 19.60%
Sales growth has been subdued in last 3 years 8.84%
Sales growth is not so good in last 4 quarters at -3.53%
Advanced Enzyme Technologies operates as a fully integrated enzyme manufacturing entity, with a significant emphasis on research and development (R&D), spanning various enzyme-related domains. While the company boasts the capability to produce enzymes from all four natural origins - plant, animal, bacterial, and fungal - its primary focus is on developing enzymes through microbial fermentation. As India's largest integrated enzyme manufacturer, Advanced Enzyme Technologies holds the second-highest market share in the country. The company boasts a diverse product portfolio, comprising over 400 proprietary products derived from 68 enzymes and probiotics.
Enzymes serve as biological catalysts, accelerating biochemical reactions within living organisms. They can be extracted from cells and applied to catalyze a broad spectrum of commercially significant processes. For instance, enzymes are crucial in the production of sweetening agents and the modification of antibiotics. They find utility in washing powders and diverse cleaning products, contributing to enhanced efficiency in removing stains and dirt. Additionally, enzymes play a pivotal role in analytical devices and assays utilized in clinical, forensic, and environmental applications, facilitating accurate detection and analysis.
The company has four business segments: (a) Human Healthcare and Nutrition, (b) Industrial bioprocessing, (c) Animal nutrition, (d) Specialised Manufacturing. Additionally, the company has a global presence and generates revenue from both Indian and international markets.
How has the company performed historically?
The past five years have presented significant challenges for the company. In FY23, there was a substantial increase in raw material prices, including soya, edible oil, and solvents like glycerine, phosphorus salts, and lithium, rising between 3-4 times. These price hikes were primarily driven by supply chain disruptions and escalated logistic costs, resulting in a decline in gross margins from 79% in FY22 to 76% in FY23. Moreover, fuel prices, including coal, surged by 2-3 times, further contributing to the escalation in manufacturing costs.
Overall, between FY19 and FY23, operating margins witnessed a notable decline of 15%, dropping from 44% in FY19 to 29% in FY23. These challenges underscore the significant impact of rising raw material and fuel prices on the company's profitability over the past five years.
The operating deleverage was combined with low sales growth of 6.5% between FY19 and FY23. These problems have been accompanied by the exit of one of the promoters, C.L. Rathi, who has now become the promoter of Advanced Vital Enzymes (Advenza), a direct competitor to Advanced Enzyme Technologies.
Understanding the Business
Human Health and Nutrition: This segment encompasses a diverse array of products, spanning anti-inflammatory, pro-digestion, and probiotic formulations, catering to a wide range of customers. These enzymes serve as active ingredients in pharmaceutical and nutraceutical formulations utilized by various clients. Key customers in this business vertical include Sanofi India, Cipla, Ipca Laboratories, Alkem Laboratories, and Emcure Pharmaceuticals.
The anti-inflammatory offering stands out as the largest revenue contributor, representing approximately 24% of sales in FY23. However, the segment's growth has experienced a modest annualized rate of 3% between FY19 and FY23, primarily attributable to a decline in revenue from the United States market.
Animal Nutrition: This segment comprises enzyme-based feed additives tailored for animal nutrition, offering essential nutrients that aid in digestion for animals. These additives promote cost-effective feed solutions, minimize animal waste, and contribute to environmental pollution mitigation. This segment has grown at an annualised rate of 10% between FY19 and FY23.
Industrial Bioprocessing: This segment involves harnessing living organisms and their components to innovate new products, offering a natural, secure, and effective approach to manufacturing. The company's industrial bioprocessing, a specialized branch of chemical engineering, concentrates on developing and producing a diverse range of products in sectors such as agriculture, polymers, and beyond. This segment has grown at an annualised rate of 12% between FY19 and FY23.
Specialised Manufacturing: This segment was introduced to the revenue stream in FY22 following the acquisition of SciTech Specialties (SSPL). This segment utilizes a unique technology known as effervescent technology to produce a variety of products for diverse industries, including health supplements, medicine, baking, cleaning solutions, and other specialized applications. Notably, these products dissolve rapidly and demonstrate effective performance.
What are the growth and margin prospects of the company?
Margins: The current margins have fallen due to an increase in raw material and power costs as previously mentioned. The raw material prices have softened over the last few quarters. Moreover, as the company undertakes new contracts, raw material costs are expected to be passed on to the customers.
The increase in general costs as a percentage of revenue can be attributed to the lack of increase in revenue to offset such costs as a percentage. As revenue from the United States and human nutrition increases, the percentage of general costs should reduce, bringing the operating margins back to 40% plus levels as witnessed historically. This is attributable to a lag effect as costs are frontloaded.
Revenue Growth:
While the growth over the last few years has been low primarily due to fall in revenue in the human nutrition business, this segment has begun recovering over the last few quarters. The growth is backed by new product launches, demand revival in end user markets, increased research & development along with acquisitions and strategic investments.
On a 9 month basis, the revenue grew by 16%. The human nutrition segment grew by 18% in 9MFY24 while bioprocessing and specialised manufacturing have grown at 17% and 30% respectively. While the animal nutrition segment has not grown on a 9 month basis, we believe that the business is strong and will continue to grow despite such fluctuations. This segment is currently the smallest and therefore, the reduction in revenue does not harm the overall growth prospects of the business unlike the earlier impact of revenue reduction in human nutrition witnessed in FY22 and FY23.
What is the competitive environment for Advanced Enzyme Technologies?
Threat of alternatives: The enzyme industry is benefitting from a shift in end consumer perceptions about the safety and use of biological inputs versus chemical inputs. As a result, players like Advanced Enzymes are increasingly replacing chemical inputs in the human and animal nutrition industry as well as pharmaceutical industry. This is one of the most important tailwinds, positioning the company positively with respect to substitutes.
Threat of competition: While the company is the largest manufacturer in India, it competes in a global market where it is among the top 15. The largest player in the market is Novonesis, created through the merger of Novozymes and Chr Hansen. Novonesis, DSM-Firmenich, BASF and other large players account for more than 75% of the total market size. However, the larger players do not compete directly with Advanced Enzymes. This is due to:
Niche products: Advanced enzymes manufactures niche products for particular clients, making the effective market quite small for such large players.
High gestation periods: The product approval cycle for enzymes is high due to the regulated nature of the business while research and development is an additional time consuming factor. Moreover, enzymes account for a small portion of overall costs, making switching based on pricing unlikely given the regulatory effort and risk involved.
Market differentiation: Novonesis is the global leader in industrial enzymes with ~50% market share, pharmaceuticals is not its key focus area and hence direct competition is limited. It is focused on industrial enzymes where Advanced Enzymes does not materially compete.
Advanced Enzyme: Q4FY23 Result Update - 19 May 2023
Q4FY23
YOY (%)
Comment
Revenue
139
5.3
The Human Nutrition segment, which contributes ~63% to overall revenue and even higher in terms of profit, continued to witness weakness on account of recessionary trends in the USA and inventory pile-up at customers’ end. Ex-Human Nutrition, the portfolio grew by 13% YoY in 4QFY23.
EBITDA
44
9.5
EBITDA Margin
31.8%
122bps
PAT
32
27
At Par Result, US business to drive forward margins.
Company share prices are keep on changing according to the market conditions. The closing price of Advanced Enzyme on 23-May-2025 10:34 is ₹291.1.
What is the market cap of Advanced Enzyme?
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-May-2025 10:34 the market cap of Advanced Enzyme stood at ₹3,232.3.
What is the P/E ratio of Advanced Enzyme?
The latest P/E ratio of Advanced Enzyme as of 23-May-2025 10:34 is 31.56.
What is the P/B ratio of Advanced Enzyme?
The latest P/B ratio of Advanced Enzyme as of 23-May-2025 10:34 is 5.14.
What is the 52-week high and low of Advanced Enzyme?
The 52-week high of Advanced Enzyme is ₹571.1 and the 52-week low is ₹257.9.
What is the TTM revenue of Advanced Enzyme?
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Advanced Enzyme is ₹351.4 ( Cr.) .
About Advanced Enzyme Technologies Ltd
The company was incorporated as a private limited company on March 15, 1989 under the provisions of the Companies Act, 1956 as Advanced Biochemicals Private Limited in Maharashtra. Pursuant to a special resolution passed by the shareholders of the Company at the extra-ordinary general meeting held on April 21, 1992, the Company was converted into a public limited company and consequently the name of the Company was changed to Advanced Biochemicals Limited. A fresh certificate of change of name reflecting the new name was issued by the Registrar of Companies, Maharashtra on May 28, 1992. Pursuant to a special resolution passed by the shareholders of their Company at the extra-ordinary general meeting held on August 8, 2005, the name of Company was further changed from Advanced Biochemicals Limited to Advanced Enzyme Technologies Limited. A fresh certificate of incorporation reflecting the new name was issued by the Registrar of Companies, Maharashtra, Mumbai on August 19, 2005.
Advanced Enzymes is a research driven company with global leadership in manufacturing of enzymes and probiotics. It is the largest Indian enzyme company engaged in the research and development, manufacturing and marketing of huge proprietary products developed from various indigenous enzymes & probiotics. The company’s aim is to help consumers’ access side-effect free healthcare, help farmers enhance nutrition for animals, and also to help the industry replace traditional thermal-chemical-mechanical processes into enzyme passed processes.
Business area of the company
The company is a fully integrated enzyme manufacturing company driven by extensive focus on research and development (R&D) of various enzymes, enzyme blends, enzyme products and customized enzyme solutions. Its experienced and qualified R&D team strives to develop creative, cost-effective unique and innovative solutions, thereby enabling their customers to develop superior products and processes. The company products assist its customers in making most of their resources, optimizing their processes, improving their product quality, saving their time and money while also mitigating the impact on the environment. It supplies these value-added and eco-safe enzyme products to diverse end-user industries like human healthcare and nutrition, animal nutrition, food processing, baking, dairy and cheese processing, fruit and vegetable processing, cereal extraction, brewing, grain processing, protein processing, oil and fat processing, biomass processing, textile processing, leather processing, paper & pulp processing, bio-fuels, bio-catalysis etc. Although, the company has the capability to manufacture enzymes using all the four natural origins viz. plant, animal, bacterial and fungal, their major focus is on developing enzymes through microbial fermentation.
Products & Solutions
Human Nutrition: The company’s enzymes are being used by a wide range of customers globally as active ingredients in their pharmaceutical and nutraceutical formulations.
Animal Nutrition: By adding its enzymes to feed, the digestibility of the feed components can be enhanced considerably.
Food Processing: The company’s enzymes play an essential role in bringing more nutrition and appeal to food & beverages products, offering significant benefits beyond the scope of traditional alternatives.
Non-Food Processing: AETL offers eco-safe solutions for a variety of industries such as textiles, leather, detergent, paper & pulp which are used in manufacturing a wide range of products.
Awards
2010: Advanced Enzymes receives Bio-Excellence in Industrial Biotech!
2010: Advanced Enzymes wins the ‘Emerging India Awards 2010’ for Life sciences-Pharmaceuticals & Chemicals segment
2011: Dr. Anil Gupta, General Manager - R&D receives the 2011 Business Leader Award from CHEMTECH foundation
2012: Advanced Enzymes Technologies Limited-received most innovative exporter's award at 'ECGC organized - D&B Indian Exporters Excellence awards.
2014: Advanced Enzymes receives Bio-Excellence in Industrial Biotech
2016: Advanced Enzymes Receives Best Nutraceutical Company of the Year Award
2017: Best IPO Award by IR Society
2018: FE CFO Awards 2018
History and Milestones
1958: Mr. L.C. Rathi sets up India's first enzyme manufacturing plant.
1978: Mr. L.C. Rathi pioneered the production of an enzyme called Papain.
1986L: Acquisition of Super Organic Research Laboratories (SORL) to begin extraction of several commercial enzymes.
1989: Establishment of Rathi Papains Pvt. Ltd. with Mr. L.C.Rathi and Mrs. Savita Rathi as it's founding directors.
1989: Advanced Biochemicals Private Ltd is incorporated to offer global and holistic enzyme solutions.
1991: Advanced Biochemicals commissioned its first fermentation facility at Sinnar, Maharashtra
1992: Advanced Biochemicals is converted from a private company to a public company and renamed as Advanced Biochemicals Limited
1993: Advanced Biochemicals sets up fermentation-based enzyme manufacturing plant with the help of foreign collaboration.
1994: SORL is merged with Advanced Biochemicals Ltd
1996: Advanced Biochemicals sets up a dedicated Application Research facility.
1997: Advanced Biochemicals turns around and reports its first profits.
2001: Advanced Biochemicals' in-house R&D labs at Thane and Sinnar are recognized by the Department of Scientific and Industrial Research (DSIR), Ministry of Science and Technology, Government of India.
2003: Sinnar Factory receives ISO 9001:2000 Systems certification.
2004: Advanced Biochemicals is ranked as the largest domestic manufacturer of Industrial Enzymes. Advanced Biochemicals files its first patent.
2005: Advanced Biochemicals Limited is renamed as Advanced Enzyme Technologies Limited (or Advanced Enzymes).
2005: Sinnar Factory receives WHO CGMP certification.
2006: Advanced Enzymes acquires 10 Acre land at Pitampur SEZ near Indore to setup state-of-the-art export oriented facility.
2007: Phase I of the export oriented fermentation facility is completed at Pitampur SEZ near Indore.
2008: Advanced Enzytech Solutions Ltd (Enzytech) is established as a subsidiary of Advanced Enzymes to cover non-food processing divisions.
2009: Advanced Enzyme Far East Ltd., a subsidiary of Advanced Enzymes is dedicated to serving the Chinese market.
2010: Advanced Enzymes is honoured with the 'Emerging India Awards 2010' for Life Science - Pharmaceuticals & Chemicals segment organized by ICICI Business Banking and CNBC TV18.
2010: Advanced Enzymes receives the Bio-Excellence 2010 award as the Best Industrial Biotech Company of the year by the department of IT-BT & ST, Govt. of Karnataka.
2011: Advanced Enzymes expands its presence in the US with the takeover of Cal India Foods International (Specialty Enzymes and Biotechnologies) as a step down subsidiary.
2012: Advanced Enzymes consolidates it presence in the US with the take over of Advanced Supplementary Technologies Corporation as a step down subsidiary.
2012: Advanced Enzymes is awarded 1st runner-up as the Most Innovative Exporter by ECGC - D&B Indian Exporters' Excellence Awards 2012.
2012: Phase II of fermentation facility is inaugurated at Pitampur SEZ near Indore.
2012: Advanced Enzymes receives its first US patent.
2013: Advanced Enzymes is ranked amongst the top 500 as part of Inc. India's fastest-growing mid-sized companies' list for 2012.
2014: Advanced Enzymes has received the Bio-Excellence award for being the Best Industrial Biotech Company at Bangalore India Bio 2014 event - the premier Biotechnology event in the country.
2014: Advanced Enzymes is ranked amongst the top 500 of India’s fastest-growing mid-sized companies list for 2013 by Inc. India.
2016: Conducts IPO & lists itself on the Indian Stock Exchanges.
2016: Acquires majority stake in JC Biotech.
2017: Acquired 100% stake in a German based company evoxx technologies GmbH.
2017: GRAS dossier was filed with USFDA
2018: 4 food enzymes got approved as a processing aid with Food Safety Standard Authority of India (FSSAI)
2018: 4 enzymes are registered with REACH –ECHA (European Chemical Agency)
Company quality is determined using minimum hurdle rate for return on capital employed and free cash flows for last 10 years.
Companies with smaller size have higher hurdle rate.
High quality stocks are important for long term investment.
Value
Valuation is computed by comparing relevant price multiples versus industry and its own history.
One unique and very important modification is our adjustment for company's financials for cyclicality and normalized profitability.
or based on whether current ratio is lower or higher than median values. See graph for better assessment.
Valuation is important for long term investment.
Actual valuation done by our Equity Analysts may differ from the Free DeciZen maker valuation. Subscribe to our premium products for more information on actual valuation
Price
Price rating is given based on stock price strength using moving averages and relative strength on shorter timeframe.
Short term time frame has little to no significance for long term investing but it can help in deciding how fast or how slow one can add a stock top your portfolio.
Only after a stock satisfies Quality and Value parameters, use price trend to build a position. Add slowly if price trend is Red or Orange. Add quickly if price trend is Green.
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:
Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
MoneyWorks4Me method for rating and ranking mutual funds for SIP
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and
ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the
various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Performance Consistency: This is measure based on whether the fund has beaten the benchmark index consistently. For
this we compare the 3-year rolling returns of the fund with the benchmark for a minimum of 5 years and preferable 10
years. The period of rolling is one month and holding period is 3 years. Fund are color-coded Green on Performance when
the fund beats the benchmark more than 90% of the time. It is Orange if it beats 80% to 90% of the time and Red if less
than 80%. Funds with less than 5 year data are color-coded Grey.
Quality of Portfolio Holding: Moneyworks4Me has color-coded stocks as Green, Orange and Red based on whether the
company's performance has generated a ROCE above a threshold level (cost of capital) over 10 years (minimum 6 years) and
generated positive Free Cash Flow. For Banks it checks whether ROE is greater than 15% and sales has grown over previous
year. Stocks that perform consistently on these combined metrics are color-coded Green (min score 14 out of 20), Orange
(between 8 and 14) and Red (less than 8 out of 20).
Fund are color-coded Green provided the portfolio has 70% holding in Green stocks but not more than 20% in Red stocks.
Funds with more than 20% Red stocks in the portfolio are color-coded Red. The rest are Orange funds
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The
ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number
that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Looking to make the most of market corrections and volatility?
Did you know that market corrections can actually present great opportunities to buy high-quality stocks at discounted prices? By taking advantage of these times of volatility, you can position your portfolio for long-term growth.
At MoneyWorks4me Portfolio Advisory, we specialize in helping investors navigate market fluctuations and build a strong, diversified portfolio. With our collaborative approach, you can maintain control over your investments while benefiting from our expertise and guidance.
If you're interested in learning more and with a minimum portfolio size of 25 L+, we can help you manage your portfolio, no matter the size. let's connect and discuss how we can work together. And as a bonus, we're offering a FREE Portfolio Review using our "Portfolio Manager" tool during our conversation.
So why wait?
Let's get started today and take your portfolio to the next level!
Best Buy Stocks
Do you want to Invest in Undervalued Handpicked stocks and earn high Returns?
Why Buy Quality Stocks
Winning and long lasting portfolio is made of Quality Stocks, but how simple is that?
Important Questions while Buying Stocks
As an Investor most important decision making questions are?
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
You can make an informed decision based on:
Q : Quality :- Q Very Good
Q Somewhat Good
Q Not Good
V : Valuation:- V+UnderValued (UV) V Somewhat UV
V Fair Value
V Somewhat OV
V+ OverValued (OV)
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Make an informed decision for Funds
You can make an informed decision based on:
P : Performance (%)* 14 Very Good
14 Somewhat Good
12 Not Good
Less than 5 year data
Q : Quality of Holding Q Very Good
Q Somewhat Good
Q Not Good
*Color code for outperformance consistency
*Number is average 3 year rolling returns
×
Want to invest successfully in stocks?
How the heck do you select a solution that ensures it?
Does it get you focused on meeting your financial goals?
Does it get you focused on meeting your financial goals?
Investing is to means to funding your goals. Your solution must help you get clarity of your goals and how you should invest to reach them. Does your solution include Financial Planning?